• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Coronary imaging trial zeroes in on plaque risk

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 11
Volume 31
Issue 11

A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.

A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.

The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial is the first study of atherosclerosis using multimodality imaging. Principal investigator Dr. Gregg W. Stone and colleagues at New York-Presbyterian Hospital/Columbia University Medical Center studied 700 patients with acute coronary syndromes using angiography, intravascular ultrasound, and virtual histology analysis of IVUS-acquired radiofrequency data.

Most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but actually have a large plaque burden and a small lumen area, the researchers found. These characteristics were invisible on the coronary angiogram but easily identifiable on IVUS. Findings were released at the 2009 Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.